Publication | Open Access

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

Tumoral PathologyMedicineCancer ManagementGynecologyRecurrent Endometrial CancerEndometrial CarcinosarcomaCancer TreatmentOncologyRadiation OncologyGynecology OncologyCancer Research